Patient journeys through metastatic castration-resistant prostate cancer: A multidisciplinary team discussion

Industry session by JANSSEN PHARMACEUTICA NV

Location: Room Madrid (Hall B2, level 0)
Chair: J.E. Gschwend, Munich (DE)

Aims and objectives of this presentation
Discuss treatment options for patients with mCRPC

18:00 - 18:05
Welcome and introduction
J.E. Gschwend, Munich (DE)

18:05 - 18:35
Beginning the journey – Chemotherapy-naïve metastatic castration-resistant prostate cancer (CRPC)
A. Alcaraz, Barcelona (ES)
K. Fizazi, Villejuif (FR)
J.E. Gschwend, Munich (DE)
N. Tunariu, London (GB)
Moderator: C. Hood, London (GB)
Interactive patient case study presentation
How the data support the management plan
Multidisciplinary team (MDT) discussion: How would we manage this patient?

18:35 - 18:55
Alternative starting points in newly confirmed metastatic CRPC
A. Alcaraz, Barcelona (ES)
K. Fizazi, Villejuif (FR)
J.E. Gschwend, Munich (DE)
N. Tunariu, London (GB)
Moderator: C. Hood, London (GB)
Interactive patient case study presentation
MDT discussion: How would we manage this patient?

18:55 - 19:25
The journey continues – Progressing metastatic CRPC
A. Alcaraz, Barcelona (ES)
K. Fizazi, Villejuif (FR)
J.E. Gschwend, Munich (DE)
N. Tunariu, London (GB)
Industry session by JANSSEN PHARMACEUTICA NV

Moderator: C. Hood, London (GB)

Interactive patient case study presentation

How the data supports the management plan

MDT discussion: How would we manage this patient?

19:25 - 19:30

Summary and close

J.E. Gschwend, Munich (DE)